US brain–computer interface startup Paradromics is rapidly emerging as a major force in the neural-device industry, having secured FDA approval to begin a human trial aimed at restoring speech in people with paralysis. The Austin-based company—already the recipient of multiple FDA Breakthrough Device designations—has now been granted Investigational Device Exemption (IDE) status for its Connect-One Early Feasibility Study (EFS), which will evaluate the Connexus BCI. This marks the first IDE approval for speech restoration using a fully implantable brain–computer interface.

Figure 1. Speech-Restoring Neural Implant Gets FDA Green Light.

The study will assess the safety and effectiveness of the Connexus system, designed to help paralyzed patients regain the ability to communicate through text or synthesized voice and to control digital devices. Built for long-term medical use, Connexus is described by the company as the first high-data-rate BCI engineered to deliver high performance for users. Figure 1 shows Speech-Restoring Neural Implant Gets FDA Green Light,

The implant is constructed from medical-grade materials, including a titanium-alloy casing and over 400 platinum–iridium electrodes positioned close to neurons. With each electrode thinner than a human hair (under 40 microns), the system performs on-chip processing to capture large volumes of neural data. During the trial, the device’s components—the cortical module, internal transceiver, and extension lead—will be implanted beneath the skin, with electrodes extending just under the brain’s surface to record signals from individual neurons in the motor cortex.

These signals travel through a subcutaneous cable to a chest-implanted transceiver, which then sends data via a secure optical link to an external transceiver worn by the patient. This external unit wirelessly powers the implant through inductive charging, similar to modern smartphone charging. The data is ultimately processed by a compact computer equipped with advanced language models and AI, which interpret neural activity to generate words—either as on-screen text or synthesized speech—or to enable control of digital devices.

This marks the first BCI study focused on generating a synthetic voice in real time, using the participants’ previous speech recordings to recreate their voices. Researchers will also test whether the implant can pick up signals from imagined hand movements, which could enable control of a computer cursor.

If early results are promising, the trial will expand to include 10 participants, with two volunteers receiving dual implants to increase the amount of neural data collected.

“It’s an exciting step,” says Mariska Vansteensel, a BCI researcher at the University Medical Center Utrecht in the Netherlands. “For the field to progress toward real clinical use, a fully implantable system is essential.”

Source: NEW ATLAS

Cite this article:

Priyadharshini S(2025), Speech-Restoration Brain Chip Wins FDA Approval for First Human Testing, AnaTechMaz, pp.428